Modality
Small Molecule
MOA
AuroraAi
Target
CD123
Pathway
Proteasome
SCLC
Development Pipeline
Preclinical
~Jun 2020
→ ~Sep 2021
Phase 1
Dec 2021
→ Sep 2029
Phase 1Current
NCT03309876
2,399 pts·SCLC
2021-12→2029-09·Recruiting
NCT07663976
1,215 pts·SCLC
2025-08→2025-11·Recruiting
3,614 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-055mo agoPh2 Data· SCLC
2029-09-053.4y awayPh2 Data· SCLC
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Recruit…
P1/2
Recruit…
Catalysts
Ph2 Data
2025-11-05 · 5mo ago
SCLC
Ph2 Data
2029-09-05 · 3.4y away
SCLC
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03309876 | Phase 1/2 | SCLC | Recruiting | 2399 | ORR |
| NCT07663976 | Phase 1/2 | SCLC | Recruiting | 1215 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 |